

organochlorines, trichloroethylene, and benzene) and genetic susceptibility. Other factors potentially related to lymphoma, such as viral infections, ultraviolet radiation exposure, medical conditions, and other lifestyle factors will also be studied. Patients from 11

participating hospitals will be screened and enrolled. There will be a one-time computer-administered interview, and patients will also be asked to provide a one-time blood and buccal cell mouth wash sample and lymphoma cases will

be asked to make available a portion of their pathology sample.

OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 3,086.

ESTIMATED ANNUALIZED BURDEN HOURS

Types of respondents	Instrument	Number of respondents	Frequency of response	Time per response (hours)	Annual burden hours
Potential Study Subjects	Screening Questions .....	1,804	1	5/60	150
Consented Patient Cases.	Core Questionnaire & Occupational Job Module	967	1	105/60	1,692
Consented Patient Controls.	Core Questionnaire & Occupational Job Module	300	1	105/60	525
Study Pathologists .....	Pathology sample request and tracking form .....	10	97	5/60	81
Interviewers .....	Tracking forms .....	15	85	30/60	638

Dated: August 24, 2015.

**Karla Bailey,**

*Project Clearance Liaison, National Cancer Institute, NIH.*

[FR Doc. 2015-21273 Filed 8-27-15; 8:45 am]

BILLING CODE 4140-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting**

**SUMMARY:** The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on September 28, 2015. The topic for this meeting will be “New Opportunities for Clinical Research on Type 2 Diabetes.” The meeting is open to the public.

**DATES:** The meeting will be held on September 28, 2015 from 1:00 p.m. to 4:30 p.m. Individuals wanting to present oral comments must notify the contact person at least 10 days before the meeting date.

**ADDRESSES:** The meeting will be held in the Democracy 2 Building at 6707 Democracy Blvd., Bethesda, MD, in Conference Room 701.

**FOR FURTHER INFORMATION CONTACT:** For further information concerning this meeting, see the DMICC Web site, [www.diabetescommittee.gov](http://www.diabetescommittee.gov), or contact Dr. B. Tibor Roberts, Executive Secretary of the Diabetes Mellitus Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 31 Center Drive, Building 31A, Room 9A19, MSC 2560, Bethesda, MD 20892-2560, telephone: 301-496-6623; FAX: 301-480-6741; email: [dmicc@mail.nih.gov](mailto:dmicc@mail.nih.gov).

**SUPPLEMENTARY INFORMATION:** The DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) comprising members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The September 28, 2015 DMICC meeting will focus on New Opportunities for Clinical Research on Type 2 Diabetes.

Any member of the public interested in presenting oral comments to the Committee should notify the contact person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives or organizations should submit a letter of intent, a brief description of the organization represented, and a written copy of their oral presentation in advance of the meeting. Only one representative of an organization will be allowed to present; oral comments and presentations will be limited to a maximum of 5 minutes. Printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the Committee by forwarding their statement to the contact person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Because of time constraints for the

meeting, oral comments will be allowed on a first-come, first-serve basis.

Members of the public who would like to receive email notification about future DMICC meetings should register for the listserv available on the DMICC Web site, [www.diabetescommittee.gov](http://www.diabetescommittee.gov).

Dated: August 21, 2015.

**B. Tibor Roberts,**

*Executive Secretary, DMICC, Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.*

[FR Doc. 2015-21291 Filed 8-27-15; 8:45 am]

BILLING CODE 4140-01-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special